January 32023
Amsterdamthe Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company dedicated to improving the lives of people living with serious autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, is at the 41stSt Annual JP Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT.
A live webcast of the presentation can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website approximately 30 days after the presentation.
About Argentx
argenx is a global immunology company dedicated to improving the lives of people living with serious autoimmune diseases. In collaboration with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate breakthrough discoveries in immunology into a world-class portfolio of novel antibody-based medicines. argenx has developed and is commercializing the first and only neonatal Fc receptor (FcRn) blocker approved in the US, Japan and the EU. The company is evaluating efgartigimod in several serious autoimmune diseases and is developing several earlier-stage investigational drugs within its therapeutic franchise. For more information visit www.argenx.com and keep following us LinkedIn, Twitterand Instagram.
For more information please contact:
Media:
Kelsey Kirk
kkirk@argenx.com
Investors:
Beth Del Giacco
bdelgiacco@argenx.com
[ad_2]
Source story
